Convatec reports strong first half 2026 results
The company remains on track for FY26, targeting growing sales, expanding margins, and double-digit adjusted EPS growth, with eight product launches scaling and eight more expected.
See the latest news and media coverage for Convatec. We track all announcements, press releases, and industry mentions in real time, all in one place.
Chronic care medical products and technologies company
convatecgroup.comLast updated
In short: Convatec reported strong 2026 growth, launched a $200 million buyback, and committed $1 billion for long-term R&D expansions.
The company remains on track for FY26, targeting growing sales, expanding margins, and double-digit adjusted EPS growth, with eight product launches scaling and eight more expected.
Fiona Ryder will step down as CFO; Tobias Hestler appointed as Non-Executive Director.
The funding will scale integrated care models and strengthen health systems in underserved regions.
Neal Carty as Chief Science & Innovation Officer and Clare Holden as Chief Quality & Regulatory Affairs Officer join the leadership team.
ConvaTec ( ) has provided an update. Convatec Group Plc has continued executing its previously announced share buyback programme of up to $200 million, repurchasing...
ConvaTec stock is underpinned by a 200 million dollar share buyback program, with recent treasury share purchases adding to ...
Investing.com - Kepler Cheuvreux has initiated coverage of ConvaTec Group PLC (LON:CTEC) with a 'Buy' rating and a target price of 286 pence. According to the...
August 4 (Reuters) - British medical products maker Convatec (CTEC.L), opens new tab on Tuesday forecast its second-half operating margin to be materially higher than...
Track Convatec and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Convatec and other trending companies.